anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators have previously observed mood improvement in participants with bipolar depression in a population aged 21-60. Here the investigators hope to extend these results to a similar but new population, geriatric bipolar depression (GPD). In addition to the evaluation of the effect of multiple treatments, as well as observation of the duration of the effect after a delay of one week in this population, the investigators will assess whether this population presents any noticeable difference in tolerance or effect.

This study was completed in two phases; the design of the second phase was revised based on results from a related study (2012P002380). The first phase had a randomized, double-blind, sham-controlled crossover design. Subjects were distributed equally into two groups; one group received three active LFMS sessions during a first treatment week and three sham LFMS sessions during a second treatment week, while the second group received sham LFMS first and then active LFMS. Specifically, all subjects made a baseline visit during week 0 (visit 1, any day) where scales of depression (Montgomery-Asberg Rating Scale (MADRS)), anxiety (Hamilton Anxiety Rating Scale (HARS)), and positive affect (Positive and Negative Affect Schedule (PANAS)) were completed. Subjects returned during week 1 for three treatment visits (visits 2,3,4 any days) during which they received active or sham LFMS according to their order assignment. Subject returned for the same mood ratings during week 2 (visit 5, any day). Subjects returned during week 3 for three treatment visits and received the alternate treatment according to their order assignment (visits 6,7,8, any days). Finally, subjects returned week 4 for to receive the mood ratings (visit 9, any day). The MADRS, HARS, and PANAS scales completed during weeks 0, 2, and 4 were the outcome measures. Treatment order assignments were randomized and balanced within blocks of 10 via a random number generator.

Following review of data from a different Low Field Magnetic Stimulation study (2012P002380), the study design was revised, and a second phase of this protocol resulted. This is a randomized, double-blind, sham-controlled study with a parallel design (subjects will either receive active treatment or sham treatment for all treatment sessions). Specifically, the MADRS, HARS, and PANAS were completed on baseline visit 1 (day 0, Friday); 5 treatment visits were made on days 3,4,5,6,7 (visits 2-6); a mood rating visit 7 was made on day 10. The MADRS, HARS, and PANAS scales completed during days 0 and 10 were the outcome measures. Treatment order assignments were randomized and balanced within blocks of 10 via a random number generator.

The mechanisms of depression in a geriatric population may differ from those in a younger population. Brain structures and connectivity have changed, and there is the increased risk of comorbid diagnoses such as dementia that might confound treatment and assessment. In this study the investigators hope to extend the findings of LFMS in the general population to directly address the treatment of bipolar depression in a geriatric population.
Cohorts of at least 3 participants each will be treated with escalating doses of SIM0348. Dose expansion part will be decided based on the findings of dose escalation part.
This study was done by two orthopedic surgeons working in three hospitals from March 2016 to April 2018, Eighty patients were involved in this study, and it was divided into 2 matched groups; Group A (40 patients) were treated with open release after diagnostic arthroscopy and Group B (40 patients) were treated by arthroscopic release. All these patients are diagnosed as lateral patellar compression syndrome depending on clinical features, MRI ( figure 1)and diagnostic arthroscopy. All patients were followed by Lysol knee scaling score before surgery , two weeks , six weeks then 6 months after surgery. The two groups are matched related to age and gender. 52 patients are females and age ranged from 21-48 years.

Exclusion criteria are 1. Smoking 2.Patellar instability 3. D.M 4. Knee osteoarthritis 5. Previous knee surgery 6. Knee deformities involving Varus , valgus or recurvatum 7. Ligament laxity
Ketamine dose will be 0.5 mg/kg. Propofol dose for the first patient will be 2.5 mg/kg. Doses for the subsequent patients will increase or decrease by 0.8 mg/kg using the Dixon Up and Down method.
PURPOSE: Omphalocele is a congenital abdominal wall defect associated with a high risk of morbidity and mortality, with co-occurring congenital malformations often being the most important prognostic factor. High rates of spontaneous and medical terminations have been reported among pregnancies with omphalocele and co-occurring malformations. Few studies have focused on co-occurring malformations, particularly non-gastrointestinal malformations among live births. This study examined birth prevalence of omphalocele and co-occurring major malformations among a 25-year Danish liveborn cohort.
METHODS: This nationwide retrospective prevalence study used data from the Danish National Patient Register and Danish Civil Registration System for infants who were delivered in Denmark during 1997-2021 and included in the Danish neonatal screening biobank. Diagnoses of omphalocele and co-occurring malformations were ascertained and prevalence estimated using Poisson regression.
RESULTS: Among 1,498,685 live births, 147 infants with omphalocele were identified, yielding a combined and stable prevalence (per 10,000 infants) of 0.98 (95% CI 0.83-1.15). Over one-half (53.7%) presented with one or more major malformations, and an additional 17.0% were diagnosed with a syndrome.
CONCLUSIONS: Omphalocele birth prevalence in Denmark was stable over a recent 25-year period. The proportion of infants with co-occurring major malformations or diagnosed syndrome has important implications for long-term healthcare demands.
The study aims to explore the relationship among metacognition (MC), fear of disease of progression (FoP), psychological distress (PD), and quality of life (QoL), and verify whether FoP and PD have a chain mediating effect between MC and QoL. 231 hematologic tumor patients in a large tertiary hospital were investigated by using Meta-Cognitions Questionnaire-30, Fear of Progression Questionnaire-Short Form, Hospital Anxiety and Depression Scale, and Functional Assessment of Cancer Therapy scale. Data analyses were performed using IBM SPSS (version 25.0) and the PROCESS macro (version 4.1). The results showed that the direct impact of MC on QoL was not statistically significant. However, the indirect influence of MC on QoL manifest through the independent influences of PD and FoP, as well as the chain mediating effect of "PD → FoP." In addition, all four dimensions of QoL (physical, social and family, emotional, and functional) satisfy the chain mediation model, except for the social and family domain. These insights advance our comprehension of the intricate interplay between MC and QoL, underscoring the importance of improving MC to alleviate patients' PD, mitigate FoP, and ultimately improve the QoL of hematologic tumor patients.
This will be a prospective cross-sectional study of 200 children aged 4 to 17 years. Participants will be assigned to either the mask type assessment (Objective 1) or the mask modification assessment (Objective 2) and have a date and time scheduled for testing.

The mask type assessment will compare the FFE and fit factor of a cloth mask, child and adult medical mask, child and adult KN95 respirator, and N95 respirator. The mask modification assessment will compare the FFE and fit factor of a child medical mask, adult medical mask with and without modifications (tuck and tie, twisted ear loops), and child and adult N95 respirator. Quantitative fit testing will be conducted using a TSI Portacount Pro Respirator Fit Tester model 8038+. Testing will be performed in an identified designated area at the hospital or in the community (i.e., schools or community center), monitored for ventilation, temperature and humidity. We will also measure the ambient particles to ensure adequate particle count. The participants will be asked to evaluate the mask, respirator or modification based on a variety of criteria including comfort, breathability and acceptability. This will be completed immediately after the fit assessment.
OBJECTIVE: The number of individuals affected by metabolic dysfunction associated fatty liver disease [1] is on the rise, yet hormonal contributors to the condition remain incompletely described and only a single FDA-approved treatment is available. Some studies suggest that the hormones ghrelin and LEAP2, which act as agonist and antagonist/inverse agonist, respectively, for the G protein coupled receptor GHSR, may influence the development of MAFLD. For instance, ghrelin increases hepatic fat whereas synthetic GHSR antagonists do the opposite. Also, hepatic steatosis is less prominent in standard chow-fed ghrelin-KO mice but more prominent in 42% high-fat diet-fed female LEAP2-KO mice.
METHODS: Here, we sought to determine the therapeutic potential of a long-acting LEAP2 analog (LA-LEAP2) to treat MAFLD in mice. LEAP2-KO and wild-type littermate mice were fed a Gubra-Amylin-NASH (GAN) diet for 10 or 40 wks, with some randomized to an additional 28 or 10 days of GAN diet, respectively, while treated with LA-LEAP2 vs Vehicle. Various metabolic parameters were followed and biochemical and histological assessments of MAFLD were made.
RESULTS: Among the most notable metabolic effects, daily LA-LEAP2 administration to both LEAP2-KO and wild-type littermates during the final 4 wks of a 14 wk-long GAN diet challenge markedly reduced liver weight, hepatic triglycerides, plasma ALT, hepatic microvesicular steatosis, hepatic lobular inflammation, NASH activity scores, and prevalence of higher-grade fibrosis. These changes were accompanied by prominent reductions in body weight, without effects on food intake, and reduced plasma total cholesterol. Daily LA-LEAP2 administration during the final 10 d of a 41.5 wk-long GAN diet challenge also reduced body weight, plasma ALT, and plasma total cholesterol in LEAP2-KO and wild-type littermates and prevalence of higher grade fibrosis in LEAP2-KO mice.
CONCLUSIONS: Administration of LA-LEAP2 to mice fed a MAFLD-prone diet markedly improves several facets of MAFLD, including hepatic steatosis, hepatic lobular inflammation, higher-grade hepatic fibrosis, and transaminitis. These changes are accompanied by prominent reductions in body weight and lowered plasma total cholesterol. Taken together, these data suggest that LEAP2 analogs such as LA-LEAP2 hold promise for the treatment of MAFLD and obesity.
Population aging generated changes in the epidemiological profile and culminated in a high frequency of diseases. The objective of this study was estimating the prevalence of multimorbidity and the associated variables in the elderly of an educational program in the Federal District of Brazil. This is a cross-sectional study with data collection carried out during the period from December 2022 to April 2023 by means of telephone calls. Multimorbidity was defined as a concomitant presence of 2 or more noncommunicable chronic diseases. One-hundred fifty individuals aged between 60 and 82 years old participated in the study. The median number of self-reported diseases was 2, ranging from 0 to 9. The estimated prevalence of multimorbidity was 69.3%, being higher among elderly individuals self-reporting their health as regular or bad/or very bad, having systemic arterial hypertension, diabetes mellitus, dyslipidaemia, hypothyroidism, overweight/obesity, and depression, including polypharmacy (P < .05). The high rate of multimorbidity and associated variables shows the importance of an integrated approach on health services focused on promoting health and preventing health impairment to favor the quality of life during aging.
Participants were randomized to wear the current power hearing aid that uses the current feedback cancellation first for 10 days. Then they wore the new power Hearing aid for another 10 days.
Eligible subjects will receive treatment sequence ABC; A= 4x25 milligrams GSK598809 capsule given in fasted state, B= 100 milligrams GSK598809 capsule in given fasted state and C= 100 milligrams GSK598809 capsule given in fed state. The treatment sequence will be followed by at least a 7-day wash-out period between each dose.
BACKGROUND: Older people with frailty are at risk of harm from immobility or isolation, yet data about how COVID-19 lockdowns affected them are limited. Falls and fractures are easily measurable adverse outcomes correlated with frailty. We investigated whether English hospital admission rates for falls and fractures varied from the expected trajectory during the COVID-19 pandemic, and how these varied by frailty status.
METHODS: NHS England Hospital Episode Statistics Admitted Patient Care data were analysed for observed versus predicted outcome rates for 24 January 2020 to 31 December 2021. An auto-regressive integrated moving average time-series model was trained using falls and fracture incidence data from 2013 to 2018 and validated using data from 2019. Models included national and age-, sex- and region-stratified forecasts. Outcome measures were hospital admissions for falls, fractures, and falls and fractures combined. Frailty was defined using the Hospital Frailty Risk Score.
RESULTS: 144,148,915 pre-pandemic hospital admissions were compared with 42,267,318 admissions after pandemic onset. For the whole population, falls and fracture rates were below predicted for the first period of national lockdown, followed by a rapid return to rates close to predicted. Thereafter, rates followed expected trends. For people living with frailty, however, falls and fractures increased above expected rates during periods of national lockdown and remained elevated throughout the study period. Effects of frailty were independent of age.
CONCLUSIONS: People living with frailty experienced increased fall and fracture rates above expected during and following periods of national lockdown. These remained persistently elevated throughout the study period.
Using General Strain Theory, this study investigates the effects of vicarious trauma exposure and perceived social support on nonmedical codeine syrup misuse among Black incarcerated men nearing community re-entry. Data were drawn from the Helping Incarcerated Men project, a study examining mental health, substance misuse, and human immunodeficiency virus (HIV) risk behaviors among Black men living in prisons who were within 180 days of release. A total of 200 Black men self-reported demographics (i.e., age and length of incarceration after age 18), vicarious trauma exposure (e.g., ever witnessing an assault with a weapon and a sudden accidental death), perceived social support, and nonmedical codeine syrup misuse. Findings from the logistic regression analysis showed witnessing an assault with a weapon and a sudden accidental death increased the likelihood of codeine syrup misuse. Perceived social support was not associated with codeine syrup misuse. Implications for practice and future research are discussed.
Hyperuricemia (HUA) may lead to myocardial cell damage, thereby promoting the occurrence and adverse outcomes of heart diseases. In this review, we discuss the latest clinical research progress, and explore the impact of HUA on myocardial damage-related diseases such as myocardial infarction, arrhythmias, and heart failure. We also combined recent findings from basic research to analyze potential mechanisms linking HUA with myocardial injury. In different pathological models (such as direct action of high uric acid on myocardial cells or combined with myocardial ischemia-reperfusion model), HUA may cause damage by activating the NOD-like receptor protein 3 inflammasome-induced inflammatory response, interfering with cardiac cell energy metabolism, affecting antioxidant defense systems, and stimulating reactive oxygen species production to enhance the oxidative stress response, ultimately resulting in decreased cardiac function. Additionally, we discuss the impact of lowering uric acid intervention therapy and potential safety issues that may arise. However, as the mechanism underlying HUA-induced myocardial injury is poorly defined, further research is warranted to aid in the development novel therapeutic strategies for HUA-related cardiovascular diseases.
A recombinant antibody molecule comprises antigen binding regions derived from the heavy and/or light chain variable regions of a donor anti-CD3 antibody, e.g. OKT3, and has anti-CD3 binding specificity, preferably of affinity similar to that of OKT3. The recombinant antibody is preferably a humanised antibody and may be a chimeric or CDR-grafted antibody. A protocol is disclosed for preparing CDR-grafted humanised antibodies in which, in addition to the CDRs non-human antibody residues are preferably used at positions 23, 24, 49, 71, 73 and 78 of the heavy chain variable region and at positions 46, 48, 58 and 71 of the light chain variable region. The recombinant, especially the humanised, anti-CD3 antibodies may be used for in vivo therapy or diagnosis. <IMAGE>
FIELD: medicine; pharmacology. SUBSTANCE: preparation has glycerol and a mixture of 40-90% alcohol tinctures and/or extracts of medicinal herbs each of which shows therapeutic activity giving at least one action from a selected group including adaptogenic, vegetotropic, immunomodulating and cerebrotropic effects. The preparation possesses all selected activity types. The preparation optionally has alcohol tinctures and/or extracts of Rhodiola rosea L. and/or Paeonia anomala L. and/or garlic and/or Herba Gnaphalii uliginosi and/or Vinca minor L. and/or Aralia melanocarpa L. and/or Sorbus aucuparia L. and/or rind of Periploca graeca L. and/or Pimpinella anisum L. and/or Mentha piperita L. and/or Folium Eucalypti viminali Labill. and/or Artemisia absinthium L. and/or Fructus Rubi idaei and/or dewberry and/or black currant and/or oak wood as the alcohol tinctures and/or extracts of medicinal herbs. The preparation is manufacturable as mixture, balsam or nutrient additive. Efficient functional psychosis prophylaxis is related to the primary activity types of a complex and extracts of the medicinal herbs. EFFECT: enhanced effectiveness of treatment; optimized condition of organs and systems in human organism. 8 cl, 2 tbl
Despite mounting evidence that nature matters for human health, we are not aware of any prospective intervention trials looking at the use of nature as a health intervention. Like other protective factors, such as the presence of a caring adult, safe play places, greater stimulation, the presence of green-space in a child's life has been empirically linked to greater resilience. Nature has been proposed as a buffer to stress through several pathways: by providing a space for friends and families to gather (thereby increasing social support and improving family relationships), by increasing opportunities for physical activity, and by improving cognition. Research to date suggests that participation in outdoor activities facilitates a sense of connectedness to place. This sense of attachment may also provide a form of social support. Families served by Children's Hospital Oakland Primary Care Clinic experience high levels of stress. As a safety-net clinic, the primary care clinic serves a diverse set of patients, with a common thread of poverty. The Stay Healthy In Nature program was developed to encourage stress management skills through play and physical activity in parks. The program uses a combination of facilitated and independent outings into local parks to encourage sustained behavior change and measurable health benefits.
The invention discloses a drug for targeted treatment of inflammatory diseases, and belongs to the field of pharmacy. The invention takes DNA aptamer modified tetrahedral framework nucleic acid of targeted TNF-alpha as a vector, and forms a complex by loading methotrexate. The compound has high encapsulation efficiency on MTX and improves the bioavailability of MTX. In an LPS-induced macrophage inflammation model, the compound disclosed by the invention can obviously reduce the ROS and NO levels of macrophages, protect the cell activity, promote the polarization of M1 type macrophages to M2 type, and reduce the expression and secretion of inflammatory factors (including IL-1 beta, IL-6 and TNF-alpha). In a collagen-induced rheumatoid arthritis rat model, the compound disclosed by the invention can be used for remarkably improving joint swelling and inflammation of a rheumatoid arthritis rat, targeting inflammatory joint tissues, relieving cartilage loss and relieving rheumatoid arthritis. The compound of the invention has simple synthesis, stable structure, excellent biological safety and absorption efficiency and wide application prospect.
Participants may receive the combination of venetoclax and revumenib for up to 1 year, and then 1 more year of venetoclax alone. You will no longer be able to take the study drug(s) if the disease gets worse or if intolerable side effects occur. Participants will take venetoclax by mouth on 1 time a day at about the same time each day, on Days 1-14 of each cycle. Take each dose with about 1 cup of water within 30 minutes after a meal, preferably breakfast.
The invention relates to tetracycline cyclohexyl sulphamate, which has a pleasant taste and is antimicrobially active.  It is prepared by reacting cyclohexyl sulphamic acid with tetracycline base in an inert organic liquid such as ethanol and separating the tetracycline cyclohexylsulphamate e.g. by addition of ether.  The tetracycline may be used therapeutically (see Division A5).ALSO:Pharmaceutical compositions for oral, topical and parenteral administration comprise tetracycline cyclohexyl sulphonate (see Division C2) and a pharmaceutical carrier.  The tetracycline derivative is water-soluble and pleasant-tasting and is particularly suitable for incorporation in buccal lozenges.  It may also be administered as tablets, capsules, pastilles, gums, syrups, powders, solutions, aerosols, gargles and mouth-washes. In admixture with alkali metal hexametaphosphate e.g. sodium hexametaphosphate, higher blood concentrations of the antibiotic are obtained on oral administration than with the antibiotic alone.
Choose traditional precise cTACE or dTACE treatment, and receive regorafenib within 2 weeks (28 days as a cycle, 80-160mg qd regorafenib orally on d1-21) and immune checkpoint inhibitors (continue treatment according to the original plan, every 3 weeks as a cycle) treatment. CT or MRI examination was repeated 4-6 weeks after the operation to evaluate whether there were active lesions. If there were still active lesions, one repeat TACE could be performed, and the number of TACE was less than 3 times.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, dermatology, and can be applied for psoriasis treatment. For this purpose ultraviolet irradiation is carried out with wavelength 311 nm. After irradiation 200 ml of ozonised physiological solution with concentration 3.5-4.0 mg/l is additionally intravenously introduced to patient in quantity of 10 procedures. Course of ultraviolet irradiation constitutes 12-15 procedures. ^ EFFECT: claimed method allows increasing of efficiency and safety of psoriasis treatment by faster and more pronounced anti-inflammatory effect, as well as reducing of total number of irradiations, due to which reduce single maximal dose and cumulative dose of irradiation. ^ 2 ex, 1 tbl